This page is updated frequently with new G Protein-related patent applications.
| Methods for diagnosing diseases associated with human signal peptide-containing molecules|
The invention provides human signal peptide-containing proteins (hspp) and polynucleotides which identify and encode hspp. The invention also provides expression vectors, host cells, antibodies, agonists, and antagonists.
| System and analysis of protein migration in serum protein electrophoresis|
A system and method for analyzing protein migration in serum protein electrophoresis is disclosed. A serum sample from a subject is collected and serum protein electrophoresis is performed to separate the plurality of proteins in the serum sample.
| Protein coated polymeric substrate|
The present invention provides a method for the functionalization of a polymeric surface with a protein by physical adsorption. The method enables a membrane spanning protein to be used as an anchor for proteins and/or peptides for display.
Orla Protein Technologies Limited
| Antibodies comprising chimeric constant domains|
Antibodies, antigen-binding proteins and fc-fusion proteins that comprise recombinant polypeptides containing a chimeric heavy chain constant region sequence are provided that bind to certain fc receptors however have reduced effector functions. Methods of making constructs for expression of such chimeric fc-containing antibodies, antigen-binding proteins and fc-fusion proteins in cell systems, and methods of producing and isolating the chimeric fc-containing proteins are provided..
Regeneron Pharmaceuticals, Inc.
| Method of inhibiting metastasis of cancer cells and modulating autoimmune diseases using gal-3bp-fc fusion protein|
A tgal-3bp-fc fusion protein, a pharmaceutical composition, an isolated nucleic acid, a recombinant expression vector, and a method of inhibiting, decreasing, reducing, suppressing or limiting metastasis of cancer cells, and immunosuppressing or modulating phagocytosis and t-cell functions by using the same are disclosed herein. The tgal-3bp-fc fusion protein comprises: a truncated gal-3 binding protein with domain 4, and at least an fc fragment of an immunoglobulin g.
Show-chwan Memorial Hospital
| Process for producing and purifying factor viii and its derivatives|
Disclosed is a method for producing proteins having factor viii procoagulant activity in serum-free medium by in vitro culturing of mammalian cells, wherein the serum-free medium contains an inhibitor against the protease released from cultured cells. In accordance with this invention, the inhibitor can protect the cleavage of a target protein during cultivation and increase homogeneity of a target molecule, wherein the inhibitor can be a dextran sulfate.
Sk Chemicals Co., Ltd.
| Pyrimido-diazepinone kinase scaffold compounds and methods of treating disorders|
The present invention relates to novel pyrimido-diazepinone compounds, methods of modulating protein kinases, including mps1 (ttk), erk5 (bmk1, mapk7), polo kinase 1, 2, 3, or 4, ack1, ack2, ab1, dcamkl1, abl1, ab1 mutants, dcamkl2, ark5, brk, mknk2, fgfr4, tnk1, plk1, ulk2, plk4, prkd1, prkd2, prkd3, ros1, rps6ka6, taok1, taok3, tnk2, bcr-ab1, gak, csrc, tpr-met, tie2, met, fgfr3, aurora, ax1, bmx, btk, c-kit, chk2, flt3, mst2, p70s6k, pdgfr, pkb, pkc, raf, rock-h, rsk1, sgk, trka, trkb and trkc, and the use of such compounds in the treatment of various diseases, disorders or conditions.. .
Dana-farber Cancer Institute, Inc.
| Dihydropteridinone derivatives and uses thereof|
The present invention provides compounds of formula (i), and pharmaceutically compositions thereof. Compounds of formula (i) are binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.
| Diazepane derivatives and uses thereof|
The present invention provides compounds of any one of formulae (i), (ii-c) (e.g., formula (ii)), and (iii), and pharmaceutically compositions thereof. Compounds of any one of formulae (i), (ii-c), and (iii) are believed to be binders of bromodomains and/or bromodomain-containing proteins (e.g., bromo and extra terminal (bet) proteins).
Dana-farber Cancer Institute, Inc.
| Anticancer adjuvant composition containing rip3 expression promoter as active ingredient, screening for anticancer adjuvant enhancing sensitivity of anticancer drug by promoting rip3 expression, and monitoring sensitivity of anticancer drug|
The present invention relates to a pharmaceutical composition for an anticancer adjuvant containing a receptor-interacting protein kinase-3 (rip3) protein expression inducing agent or activator as an active ingredient. The present invention also provides a method for enhancing cancer cell death, comprising administering a rip3 protein expression inducing agent or activator in combination with an anticancer drug to cancer cells.
Dong Wha Pharm. Co., Ltd.
Compositions and methods for quantitative assessment of dna-protein complex density
One aspect of the present invention describes materials and methods of quantitatively measuring the density or percent occupancy of dna binding proteins such as histones, histone variants, histone post translational modifications and transcription factors in chromatin at given dna loci. One embodiment measures a factor's average quantity at specific gene loci, and controls for a number of pitfalls concerning antibody quality and handling issues.
The University Of Chicago
Biological sensing separating biomolecule
A biological sensing device and a method for separating a biomolecule are provided. The biological sensing device includes an amino acid sequence and a signal-generating unit.
National Chiao Tung University
Rapid protein labeling and analysis
The present invention provides methods and compositions for labeling, separating and analyzing proteins, particularly a specific protein of interest within a cell lysate or in a mixture of proteins. The proteins are labeled with an amine reactive or thiol reactive fluorescent dye, or an amine reactive fluorogenic reagent that becomes fluorescent upon reacting to amine groups located on the protein.
Life Technologies Corporation
Method for optimizing post-translational modifications on recombinant proteins
A method for optimizing post-translational modifications of recombinant proteins expressed in living cells is described. More particularly, a method for modulation of host proteins in living cells that control ptms on recombinant proteins is described that has particularly useful applications in developing manufacturing process changes or in biosimilar development.
Trispecific binding proteins and methods of use
Provided herein are trispecific antigen-binding proteins comprising a domain binding to cd3, a half-life extension domain, and a domain binding to a target antigen. Also provided are pharmaceutical compositions thereof, as well as nucleic acids, recombinant expression vectors and host cells for making such trispecific antigen-binding proteins.
Harpoon Therapeutics, Inc.
Multimeric complexes with improved in vivo stability, pharmacokinetics and efficacy
The present invention concerns multimeric complexes based on antibody fusion proteins comprising an ad moiety attached to the c-terminal end of each antibody light chain. The complexes further comprise effector moities attached to ddd moieties.
Ibc Pharmaceuticals, Inc.
Anti-mesothelin binding proteins
The present disclosure provides compositions and methods relating to antigen binding proteins, in particular, antibodies and bispecific antibodies which specifically bind to mesothelin. The disclosure provides nucleic acids encoding such antigen binding proteins and antibodies and methods of making and using such antibodies, including methods of treating and preventing cancer or other hypoproliferative disorders and related disorders by administering such antigen binding proteins and antibodies to a subject in need of such treatment..
Human c-fms antigen binding proteins
Antigen binding proteins that bind to human c-fms protein are provided. Nucleic acids encoding the antigen binding protein, vectors, and cells encoding the same are also provided.
The invention provides antibodies that specifically bind to pd-l1 and fusion molecules comprising pd-l1 binding proteins constructed with an il15 receptor-binding domain, nucleic acid molecules encoding the same, and therapeutic compositions thereof. The agents inhibit pd-l1-mediated immunosuppression and enhance cell and cytokine mediated immunity for the treatment of neoplastic and infectious diseases..
Kadmon Corporation, Llc
Self-buffering protein formulations
The invention herein described, provides, among other things, self-buffering protein formulations. Particularly, the invention provides self-buffering pharmaceutical protein formulations that are suitable for veterinary and human medical use.
Coronavirus proteins and antigens
Disclosed herein are embodiments of a method for collecting, extracting or eluting proteins and antigens from cells infected with coronavirus. The coronavirus may be a porcine coronavirus, such as porcine epidemic diarrhea virus (pedv) or porcine delta coronavirus (pdcov).
Mj Biologics, Inc.
Methods and kits for isolation and analysis of a chromatin region
The present invention encompasses methods of identifying proteins and protein modifications of proteins specifically associated with a chromatin.. .
Board Of Trustees Of The University Of Arkansas
Method and materials to deplete impurities for extraction and purification of nucleic acids from stool
Provided herein is materials and method relating to nucleic acids extraction and purification from biological samples such as stool. In particular, binding protein(s) is used to facilitate the extraction and purification of nucleic acids from stool samples, more specifically, depleting and blocking inhibitors and impurities from stool samples and resulting in a highly concentrated and purified nucleic acids preparation..
Methods and products for transfecting cells
The present invention relates in part to nucleic acids encoding proteins, nucleic acids containing non-canonical nucleotides, therapeutics comprising nucleic acids, methods, kits, and devices for inducing cells to express proteins, methods, kits, and devices for transfecting, gene editing, and reprogramming cells, and cells, organisms, and therapeutics produced using these methods, kits, and devices. Methods for inducing cells to express proteins and for reprogramming and gene-editing cells using rna are disclosed.
Factor Bioscience Inc.
Viral vector production system
The present invention relates to a nucleic acid sequence comprising a binding site operably linked to a nucleotide of interest, wherein the binding site is capable of interacting with an rna-binding protein such that translation of the nucleotide of interest is repressed in a viral vector production cell.. .
Oxford Biomedica (uk) Limited
Microorganism including gene encoding protein having hydroxylase activity and reducing concentration of fluorinated methane in sample using the same
A microorganism including a foreign gene encoding a protein having a hydroxylase activity that reduces the concentration of chnf4-n (n is an integer of 0 to 3) in a sample, as well as a composition including the microorganism or lysate thereof, and a method of reducing the concentration of chnf4-n in a sample using the microorganism or lysate.. .
Samsung Electronics Co., Ltd.
Tethering cysteine residues using cyclic disulfides
Described herein are compounds and methods for tethering proteins. For example, dimers of proteins, including sod1 and dj-1, are described, where the dimers are formed by the covalent bonding of a cysteine on the first monomer to a cysteine on the second monomer via a cyclic disulfide linker.
Chimeric antigen receptor compositions
Provided herein are compositions which exhibit novel diagnostic capabilities and allow to rapidly add functionality to adoptive immunotherapy. The compositions include isolated nucleic acids encoding proteins including antibody regions capable of binding compounds including a peptidyl moiety (e.g., a meditope).
City Of Hope
Deimmunized serum-binding domains and their use in extending serum half-life
The present invention is directed to a polypeptide (for example, an antigen-binding molecule) that comprises a polypeptide portion of a deimmunized serum-binding protein capable of binding to said serum protein. The presence of the serum-binding protein extends the serum half-life of the polypeptide, relative to the serum half-life of the polypeptide if lacking the polypeptide portion of the deimmunized serum-binding protein.
Antibodies against tl1a and uses thereof
The disclosure provides tnf-like ligand 1a (tl1a)-binding proteins comprising an antigen binding domain of an antibody which binds specifically to tl1a and inhibits interaction of tl1a and death receptor 3 (dr3) and which does not inhibit the interaction of tl1a and decoy receptor 3 (dcr3). The disclosure also provides uses of the tl1a-binding proteins..
Teva Pharmaceuticals Australia Pty Ltd
Antigen binding proteins
The present invention relates to antigen binding proteins, such as antibodies, which bind to serum amyloid p component (sap), polynucleotides encoding such antigen binding proteins, pharmaceutical compositions comprising said antigen binding proteins and methods of manufacture. The present invention also concerns the use of such antigen binding proteins in the treatment or prophylaxis of diseases associated with amyloid deposition including systemic amyloidosis, local amyloidosis, alzheimer's disease, and type 2 diabetes..
Glaxo Group Limited
Small molecule composite surfaces as inhibitors of protein-protein interactions
A method of inhibiting a binding event between a target protein and a binding protein, comprising administering to a cell in vitro an effective amount of a non-naturally occurring bifunctional inhibitor molecule including (a) protein binding moiety, and (b) an effector region, wherein the protein binding moiety binds to a blocking protein, and wherein the effector region binds to the target protein in order to bind the target protein and the blocking protein and prevent access of the binding protein to the target protein. This abstract is intended as a scanning tool for purposes of searching in the particular art and is not intended to be limiting of the present invention..
G Protein topics:
Protein A Affinity Chromatography
Follow us on Twitter
This listing is a sample listing of patent applications related to G Protein for is only meant as a recent sample of applications filed, not a comprehensive history. There may be associated servicemarks and trademarks related to these patents. Please check with patent attorney if you need further assistance or plan to use for business purposes. This patent data is also published to the public by the USPTO and available for free on their website. Note that there may be alternative spellings for G Protein with additional patents listed. Browse our RSS directory or Search for other possible listings.